Generic molecule: ocriplasmin
Approval date: Oct. 18
The scoop: The approval of ocriplasmin marked the first time a drug has been available for treatment of symptomatic vitreomacular adhesion, which is currently treated surgically. The company experienced strong growth in 2012, in part due to an FDA panel recommendation for approval of ocriplasmin in July. Peak sales are estimated at about $900 million, Reuters reported.